Redcliffe Lifetech raises $61 million to expand access to diagnostic tests across India

The investment will be used to expand Redcliffe’s geographic reach across India, with a focus on expanding its direct to consumer diagnostics into tier 2, 3 and 4 cities, providing pathology services from glucose to genetics

Redcliffe Lifetech (Redcliffe) has announced that it has raised $61 million led by LeapFrog Investments (LeapFrog), with participation from Healthquad, Schroders, LC Nueva, Growth Spark Ventures and existing investors Chiratae Ventures and Alkemi Venture Partners.

The investment will be used to expand Redcliffe’s geographic reach across India, with a focus on expanding its direct to consumer diagnostics into tier 2, 3 and 4 cities, providing pathology services from glucose to genetics.

Funding will also be used to scale Redcliffe’s platform and increase its product offerings to radiology, disease data profiling and lifestyle management, furthering its mission to shift India’s healthcare focus from treatment to early diagnosis and prevention. 

Redcliffe delivers its diagnostics services in its network of 22 labs across 14 cities, several of which are already NABL accredited.

O3 capital acted as financial advisor on the transaction.